To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
A phase 2/3 trial testing IAH0968 in gastric & gastro-oesophageal junction cancer, now recruiting.
Overview
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer is a phase 2/3 interventional study registered as NCT06504732, led by SUNHO（China）BioPharmaceutical CO., and recruiting when checked on 2026-09-11. Official title: A Phase II/III Clinical Study Evaluating IAH0968 in Combination or Not in Combination With the CAPEOX Regimen in HER2-expressing Advanced/Metastatic Solid Tumours and Gastric Cancer. Planned enrolment is 574 participants (estimated). The study started in 2024-08-15 and primary completion is expected in 2028-07. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Shares Hutchmed and the tag ctgov-ingest.
- TrialHMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
Shares Hutchmed and the tag ctgov-ingest.
- TrialA Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Shares Hutchmed and the tag ctgov-ingest.
- TrialA Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialM108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialSymbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialA Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.